Trial reportClinical cancer research : an official journal of the American Association for Cancer Research2020
Low-dose versus High-dose Carfilzomib with Dexamethasone (S1304) in Patients with Relapsed-Refractory Multiple Myeloma.
Trial report in Clinical cancer research : an official journal of the American Association for Cancer Research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 19 citations in OpenAlex.
- Carfilzomib prescribing patterns and outcomes for relapsed or refractory multiple myeloma: a real-world analysis.Blood cancer journal · 2025Article
- Evidence-based Korean guidelines for the clinical management of multiple myeloma: addressing 12 key clinical questions.Blood research · 2025Review
- Real-world comparison of daratumumab-based regimens in relapsed/refractory multiple myeloma using health record data.Blood neoplasia · 2024Article
- A systematic review and meta-analysis of carfilzomib-associated thrombocytopenia as an adverse event in patients with multiple myeloma.Therapeutic advances in hematology · 2024Article
- Article
- Cardiovascular Toxicity of Proteasome Inhibitors: Underlying Mechanisms and Management Strategies:JACC. CardioOncology · 2023Review
- Treatment preferences of patients with relapsed or refractory multiple myeloma in the United States, United Kingdom, Italy, Germany, France, and Spain: results from a discrete choice experiment.Frontiers in medicine · 2023Article
- Real-world effectiveness and safety analysis of carfilzomib-lenalidomide-dexamethasone and carfilzomib-dexamethasone in relapsed/refractory multiple myeloma: a multicenter retrospective analysis.Therapeutic advances in hematology · 2022Article
- A decision process for drug discovery in retinoblastoma.Investigational new drugs · 2021Article
- A study of carfilzomib and dexamethasone in patients with relapsed and refractory multiple myeloma in China.International journal of hematology · 2021Article
- The role of carfilzomib in relapsed/refractory multiple myeloma.Therapeutic advances in hematology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 13 institutions in 1 country.
Funding
Abstract
purposeTreatment of multiple myeloma has evolved tremendously and optimal utilization of available therapies will ensure maximal patient benefits. PATIENTS AND
methodsWe report the Southwest Oncology Group randomized phase II trial (S1304) comparing twice weekly low-dose (27 mg/m
resultsAmong 143 enrolled patients, of whom 121 were eligible and analyzable, the overall response rate was 42.8%, with no significant difference between the arms (
conclusionsThis randomized trial did not support a benefit of fixed duration, twice weekly 56 mg/m
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.